ArticleFrontiers in cardiovascular medicine2026
Efficacy and safety of renal denervation in patients with refractory ventricular electrical storm.
Article in Frontiers in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Ventricular electrical storm (ES) is a malignant arrhythmia that seriously threatens the patients' life. Renal denervation (RDN) has been described as a treatment modality for refractory ventricular arrhythmias. This study aims to explore the potential role in patients with ablation-refractory ES. Methods: This single-center retrospective cohort study included patients with refractory ES who underwent RDN between 2023 and 2024 with a follow-up period for 2-6 months. Implantable cardioverter defibrillator (ICD) programming results and intraoperative parameters were collected. Patients' clinical examination results were also compiled. Results: The study involved 10 patients with a mean age of 57.9 ± 7.4 years, including 4 (40%) ischemic cardiomyopathy, 6 (60%) dilated cardiomyopathy and 6 (60%) hypertension. ICD therapies showed a decreasing trend after multimodal therapy including RDN [pre-RDN 22 [9.3, 41], post-RDN 2.5 [0, 26.3]]. ICD shock therapies exhibited a similar descending tendency [pre-RDN 8.5 [1, 12.8] and post-RDN 0.5 [0, 3.5]]. Echocardiography and plasma results remained unchanged before and after surgery, including ejection fraction, left ventricular end-systolic diameter, left ventricular end-diastolic diameter, and creatinine concentration. Conclusion: Multimodal therapy including RDN may has the potential to contribute to decrease ICD therapies for patients with ES. Larger sample investigations may further demonstrate the efficacy and safety of RDN.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.